These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11035197)

  • 21. Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle.
    Gratieri T; Pujol-Bello E; Gelfuso GM; de Souza JG; Lopez RF; Kalia YN
    Eur J Pharm Biopharm; 2014 Feb; 86(2):219-26. PubMed ID: 23791718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Invasive Transdermal Delivery of Antisense Oligonucleotides with Biocompatible Ionic Liquids.
    Toyofuku K; Wakabayashi R; Kamiya N; Goto M
    ACS Appl Mater Interfaces; 2023 Jul; 15(28):33299-33308. PubMed ID: 37405761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
    Geary RS; Norris D; Yu R; Bennett CF
    Adv Drug Deliv Rev; 2015 Jun; 87():46-51. PubMed ID: 25666165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma.
    Finotto S; Buerke M; Lingnau K; Schmitt E; Galle PR; Neurath MF
    J Allergy Clin Immunol; 2001 Feb; 107(2):279-86. PubMed ID: 11174194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of delivery systems to improve target efficacy of oligonucleotides.
    Shoji Y; Nakashima H
    Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel non-endocytic delivery of antisense oligonucleotides.
    Dokka S; Rojanasakul Y
    Adv Drug Deliv Rev; 2000 Oct; 44(1):35-49. PubMed ID: 11035196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation.
    Regnier V; Préat V
    Pharm Res; 1998 Oct; 15(10):1596-602. PubMed ID: 9794503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted delivery of antisense oligonucleotides by molecular conjugates.
    Bunnell BA; Askari FK; Wilson JM
    Somat Cell Mol Genet; 1992 Nov; 18(6):559-69. PubMed ID: 1287854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal delivery of macromolecules using skin electroporation.
    Lombry C; Dujardin N; Préat V
    Pharm Res; 2000 Jan; 17(1):32-7. PubMed ID: 10714605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electroporation as an efficient physical enhancer for skin drug delivery.
    Escobar-Chávez JJ; Bonilla-Martínez D; Villegas-González MA; Revilla-Vázquez AL
    J Clin Pharmacol; 2009 Nov; 49(11):1262-83. PubMed ID: 19717723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent and selective gene inhibition using antisense oligodeoxynucleotides.
    Flanagan WM; Wagner RW
    Mol Cell Biochem; 1997 Jul; 172(1-2):213-25. PubMed ID: 9278247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
    Astriab-Fisher A; Sergueev D; Fisher M; Shaw BR; Juliano RL
    Pharm Res; 2002 Jun; 19(6):744-54. PubMed ID: 12134943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electroporation-mediated delivery of 3'-protected phosphodiester oligodeoxynucleotides to the skin.
    Regnier V; Tahiri A; André N; Lemaître M; Le Doan T; Préat V
    J Control Release; 2000 Jul; 67(2-3):337-46. PubMed ID: 10825565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of antisense oligonucleotides.
    Agrawal S; Temsamani J; Galbraith W; Tang J
    Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense oligonucleotide pharmacokinetics and metabolism.
    Geary RS
    Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):381-91. PubMed ID: 19379126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspects of the transport and delivery of antisense oligonucleotides.
    Juliano RL; Yoo H
    Curr Opin Mol Ther; 2000 Jun; 2(3):297-303. PubMed ID: 11249624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Weyermann J; Lochmann D; Georgens C; Zimmer A
    Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides.
    Moulds C; Lewis JG; Froehler BC; Grant D; Huang T; Milligan JF; Matteucci MD; Wagner RW
    Biochemistry; 1995 Apr; 34(15):5044-53. PubMed ID: 7536034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells.
    Fimmel S; Saborowski A; Orfanos CE; Zouboulis CC
    Horm Res; 2000; 54(5-6):306-11. PubMed ID: 11595823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.